SHANGHAI, China, November 25, 2025 — Phrontline Biopharma (“Phrontline”), a next-generation antibody–drug conjugate (ADC) company, today announced the closing of a $60 million Pre-A+ financing round. The round was led by Lapam Investment, with participation from Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing shareholders — Decheng Capital, Medfine Health Fund, and C&D Emerging Investment — also participated and increased their investment in the company.This financing reflects strong investor confidence in Phrontline’s differentiated bispecific and dual-payload ADC platforms, its strategically designed pipeline, and its rapidly expanding global development capabilities. Proceeds will support advancement of the company’s clinical-stage and preclinical ADC programs, expansion of global clinical operations, and strengthening of key strategic partnerships.

Shanghai, China & Incheon, South Korea – Phrontline Biopharma, a clinical-stage biotechnology company dedicated to developing a new generation of Antibody-Drug Conjugates (ADCs), today announced it has entered a global strategic collaboration with Samsung Bioepis Co., Ltd. to jointly develop best-in-class ADC therapies for the treatment of solid tumors.

SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology.

Phrontline Biopharma is pleased to announce that its first bispecific ADC program, TJ101, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone marks the company’s official transition into the clinical stage, showcasing its strong R&D capabilities in the ADC field and offering new therapeutic hope to patients worldwide.